6 active not recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Locally Advanced Urethral Urothelial Carcinoma: new trials by email Literature Review of Locally Advanced Urethral Urothelial Carcinoma trials Research Report on Locally Advanced Urethral Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
Ureteral Neoplasms (5) · Urethral Neoplasms (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Transitional Cell (4) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1)
Neoplasms (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Ureteral Diseases (5) · Urethral Diseases (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4)
Nivolumab (4) · Specimen Handling (2) · atezolizumab (2) · avelumab (2) · pembrolizumab (2) · Biopsy (1) · CTLA-4 Antigen (1) · Contrast Media (1) · Disulfides (1) · Immunoglobulin G (1) · Ipilimumab (1) · Propranolol (1) · durvalumab (1) · enfortumab vedotin (1) · erdafitinib (1)
M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1)
United States (6) · Canada (1)
Anishka A D'Souza (1) · Jacqueline Brown, MD (1) · Rodabe Amaria, MD (1) · Rohit Jain (1) · Sangeeta Goswami (1) · Xiao X. Wei, MD, MAS (1)
P30CA138292 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186717 (1)